<span item_type="fundamental" item_id="3b77fe4942179360b0d4fe81fc82e7b2" counter_id="ST/US/CLDX" env="prod"></span><span item_type="announcement" item_id="620123283543754881" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 1.545 M.</p><p>EPS: As of FY2025, the actual value is USD -3.9, missing the estimate of USD -3.6736.</p><p>EBIT: As of FY2025, the actual value is USD -287.37 M.</p><p></p><h4>Overall Company Financial Performance</h4><h5>Net Loss</h5><p>Celldex Therapeutics, Inc. reported a net loss of - $258.8 million in 2025, - $157.9 million in 2024, and - $141.4 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Operating Loss</h5><p>The company’s operating loss was - $287.4 million in 2025, - $195.1 million in 2024, and - $154.5 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Total Revenues</h5><p>Total revenues for Celldex Therapeutics, Inc. were $1.5 million in 2025, $7.0 million in 2024, and $6.9 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>General and Administrative Expenses</h5><p>General and administrative expenses amounted to $43.8 million in 2025, representing a 14% increase from 2024, and $38.5 million in 2024, a 25% increase from 2023, with 2023 expenses at $30.9 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Litigation Settlement Related Loss</h5><p>A litigation settlement related loss of $12.5 million was recorded in 2023, due to a milestone payment under the Settlement Agreement with SRS.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Investment and Other Income, Net</h5><p>Investment and other income, net, was $28.6 million in 2025, a 23% decrease from 2024; $37.2 million in 2024, a 184% increase from 2023; and $13.1 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Liquidity</h5><p>As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $518.6 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Cash Flow from Operating Activities</h5><p>Cash flow from operating activities was - $210.9 million in 2025, - $157.8 million in 2024, and - $107.3 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Cash Flow from Investing Activities</h5><p>Investing activities provided $209.1 million in 2025, used - $290.1 million in 2024, and used - $105.8 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Cash Flow from Financing Activities</h5><p>Financing activities provided $2.4 million in 2025, $441.4 million in 2024, and $218.5 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Net Proceeds from Stock Issuances</h5><p>Net proceeds from stock issuances included $432.3 million from an underwritten public offering in 2024 and $216.2 million from an underwritten public offering in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h4>Research and Development Expenses by Program</h4><h5>Total Research and Development Expense</h5><p>Total research and development expense was $245.1 million in 2025, a 50% increase from 2024; $163.6 million in 2024, a 39% increase from 2023; and $118.0 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Barzolvolimab/Anti-KIT Program</h5><p>Expenses for the Barzolvolimab/Anti-KIT Program were $198.3 million in 2025, $123.8 million in 2024, and $79.9 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>CDX-622 Program</h5><p>The CDX-622 Program incurred expenses of $19.0 million in 2025, $17.3 million in 2024, and $16.3 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h5>Other Programs</h5><p>Other programs had expenses of $27.8 million in 2025, $22.5 million in 2024, and $21.8 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p><h4>Outlook and Guidance</h4><p>Celldex Therapeutics, Inc. anticipates a decrease in revenue over the next twelve months due to reduced services under agreements with Rockefeller University, despite potential quarterly fluctuations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span> The company projects increases in personnel, product development, and general and administrative expenses to support the expanded development of barzolvolimab and commercial planning efforts.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span> While current cash, cash equivalents, and marketable securities are expected to fund operations through 2027, additional capital may be required for long-term liquidity, potentially through dilutive offerings or significant payment obligations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm"></span></p>

Celldex Therap | 10-K: FY2025 Revenue: USD 1.545 M